Prasugrel Inappropriate Use in Patients Post-percutaneous coronary intervention (PCI). A Single Center Study

Prasugrel Inappropriate Use in Patients Post-percutaneous coronary intervention (PCI). A Single Center Study

Prasugrel is a thienopyridine that was approved by the US Food and Drug Administration (FDA) in combination with aspirin for the reduction of thrombotic events as well as stent thrombosis in patients with ACS who undergo PCI. This retrospective study aims to assess the frequency of inappropriate use...

Full description

Bibliographic Details
Main Authors: Ahmed Amro, Kanaan Mansoor, Mohammad Amro, Amal Sobeih, Obadah Aqtash, Hisham Hirzallah, Alaa Gabi, Madhulika Urella, Waseem Ahmed, Sandra Shenouda, Rameez Sayyed
Format: Article
Language:English
Published: Marshall University 2019-07-01
Series:Marshall Journal of Medicine
Subjects:
Prasugrel
inappropriate use
Coronary intervention
DAPT
Online Access:https://mds.marshall.edu/cgi/viewcontent.cgi?article=1220&context=mjm
id doaj-ec9e53e19f8f4a7ea9aa69bbdb08b608
record_format Article
spelling doaj-ec9e53e19f8f4a7ea9aa69bbdb08b6082020-11-25T01:24:45ZengMarshall UniversityMarshall Journal of Medicine 2379-95362019-07-0153303610.33470/2379-9536.1220Prasugrel Inappropriate Use in Patients Post-percutaneous coronary intervention (PCI). A Single Center StudyAhmed Amro0Kanaan Mansoor1Mohammad Amro2Amal Sobeih3Obadah Aqtash4Hisham Hirzallah5Alaa Gabi 6Madhulika Urella7Waseem Ahmed 8Sandra Shenouda9Rameez Sayyed10Marshall University Joan C. Edwards School of MedicineMarshall University Joan C. Edwards School of MedicineSchool of Medicine, MUST – Misr University for Science & TechnologySchool of Medicine, Al-Najah UniversityMarshall University Joan C. Edwards School of MedicineMarshall University Joan C. Edwards School of MedicineMarshall University Joan C. Edwards School of MedicineMarshall University Joan C. Edwards School of MedicineMarshall University Joan C. Edwards School of MedicineMarshall University Joan C. Edwards School of MedicineMarshall University Joan C. Edwards School of MedicinePrasugrel is a thienopyridine that was approved by the US Food and Drug Administration (FDA) in combination with aspirin for the reduction of thrombotic events as well as stent thrombosis in patients with ACS who undergo PCI. This retrospective study aims to assess the frequency of inappropriate use of prasugrel and to emphasize that prasugrel still needs more attention as inappropriate use may result in significant morbidity.https://mds.marshall.edu/cgi/viewcontent.cgi?article=1220&context=mjmPrasugrelinappropriate useCoronary interventionDAPT
collection DOAJ
language English
format Article
sources DOAJ
author Ahmed Amro
Kanaan Mansoor
Mohammad Amro
Amal Sobeih
Obadah Aqtash
Hisham Hirzallah
Alaa Gabi
Madhulika Urella
Waseem Ahmed
Sandra Shenouda
Rameez Sayyed
spellingShingle Ahmed Amro
Kanaan Mansoor
Mohammad Amro
Amal Sobeih
Obadah Aqtash
Hisham Hirzallah
Alaa Gabi
Madhulika Urella
Waseem Ahmed
Sandra Shenouda
Rameez Sayyed
Prasugrel Inappropriate Use in Patients Post-percutaneous coronary intervention (PCI). A Single Center Study
Marshall Journal of Medicine
Prasugrel
inappropriate use
Coronary intervention
DAPT
author_facet Ahmed Amro
Kanaan Mansoor
Mohammad Amro
Amal Sobeih
Obadah Aqtash
Hisham Hirzallah
Alaa Gabi
Madhulika Urella
Waseem Ahmed
Sandra Shenouda
Rameez Sayyed
author_sort Ahmed Amro
title Prasugrel Inappropriate Use in Patients Post-percutaneous coronary intervention (PCI). A Single Center Study
title_short Prasugrel Inappropriate Use in Patients Post-percutaneous coronary intervention (PCI). A Single Center Study
title_full Prasugrel Inappropriate Use in Patients Post-percutaneous coronary intervention (PCI). A Single Center Study
title_fullStr Prasugrel Inappropriate Use in Patients Post-percutaneous coronary intervention (PCI). A Single Center Study
title_full_unstemmed Prasugrel Inappropriate Use in Patients Post-percutaneous coronary intervention (PCI). A Single Center Study
title_sort prasugrel inappropriate use in patients post-percutaneous coronary intervention (pci). a single center study
publisher Marshall University
series Marshall Journal of Medicine
issn 2379-9536
publishDate 2019-07-01
description Prasugrel is a thienopyridine that was approved by the US Food and Drug Administration (FDA) in combination with aspirin for the reduction of thrombotic events as well as stent thrombosis in patients with ACS who undergo PCI. This retrospective study aims to assess the frequency of inappropriate use of prasugrel and to emphasize that prasugrel still needs more attention as inappropriate use may result in significant morbidity.
topic Prasugrel
inappropriate use
Coronary intervention
DAPT
url https://mds.marshall.edu/cgi/viewcontent.cgi?article=1220&context=mjm
work_keys_str_mv AT ahmedamro prasugrelinappropriateuseinpatientspostpercutaneouscoronaryinterventionpciasinglecenterstudy
AT kanaanmansoor prasugrelinappropriateuseinpatientspostpercutaneouscoronaryinterventionpciasinglecenterstudy
AT mohammadamro prasugrelinappropriateuseinpatientspostpercutaneouscoronaryinterventionpciasinglecenterstudy
AT amalsobeih prasugrelinappropriateuseinpatientspostpercutaneouscoronaryinterventionpciasinglecenterstudy
AT obadahaqtash prasugrelinappropriateuseinpatientspostpercutaneouscoronaryinterventionpciasinglecenterstudy
AT hishamhirzallah prasugrelinappropriateuseinpatientspostpercutaneouscoronaryinterventionpciasinglecenterstudy
AT alaagabi prasugrelinappropriateuseinpatientspostpercutaneouscoronaryinterventionpciasinglecenterstudy
AT madhulikaurella prasugrelinappropriateuseinpatientspostpercutaneouscoronaryinterventionpciasinglecenterstudy
AT waseemahmed prasugrelinappropriateuseinpatientspostpercutaneouscoronaryinterventionpciasinglecenterstudy
AT sandrashenouda prasugrelinappropriateuseinpatientspostpercutaneouscoronaryinterventionpciasinglecenterstudy
AT rameezsayyed prasugrelinappropriateuseinpatientspostpercutaneouscoronaryinterventionpciasinglecenterstudy
_version_ 1725117418375741440

Similar Items